Ramucirumab: First Global Approval

An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer

(2014) R. Garcia-Carbonero et al.   ONCOLOGIST

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

(2013) A. X. Zhu et al.   CLINICAL CANCER RESEARCH

Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use

(2013) Giuseppe Aprile et al.   DRUGS

Targeted inhibition of VEGF receptor 2: an update on ramucirumab

(2013) Jeffrey Melson Clarke et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

VEGFA and tumour angiogenesis

(2013) L. Claesson-Welsh et al.   JOURNAL OF INTERNAL MEDICINE

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications

(2012) Catherine Frenette   WORLD JOURNAL OF GASTROENTEROLOGY

The Structural Basis for the Function of Two Anti-VEGF Receptor 2 Antibodies

(2011) Matthew C. Franklin et al.   STRUCTURE

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

(2010) Jennifer L. Spratlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor

(2009) Jerry Y. Hsu et al.   BIODRUGS